113 related articles for article (PubMed ID: 29433805)
1. Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits.
Tanno L; Mayo D; Mills S; Takhar A; Cave J; Nolan L; Stedman B; Sundram FX; Abu Hilal M; Connor H; Pearce N; Armstrong T
Pancreatology; 2018 Apr; 18(3):304-312. PubMed ID: 29433805
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
Nissen NN; Kim AS; Yu R; Wolin EM; Friedman ML; Lo SK; Wachsman AM; Colquhoun SD
Am Surg; 2009 Oct; 75(10):1025-9. PubMed ID: 19886158
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study.
Yadav S; Sharma P; Zakalik D
Am J Clin Oncol; 2018 May; 41(5):485-491. PubMed ID: 27322698
[TBL] [Abstract][Full Text] [Related]
4. A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands.
Genc CG; Klümpen HJ; van Oijen MGH; van Eijck CHJ; Nieveen van Dijkum EJM
World J Surg; 2018 Feb; 42(2):490-497. PubMed ID: 29018912
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
7. Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).
Manfredi S; Walter T; Baudin E; Coriat R; Ruszniewski P; Lecomte T; Laurenty AP; Goichot B; Rohmer V; Roquin G; Cojocarasu OZ; Lombard-Bohas C; Lepage C; Morcet J; Cadiot G
Endocrine; 2017 Sep; 57(3):504-511. PubMed ID: 28664309
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas.
Folkert IW; Hernandez P; Roses RE
World J Gastroenterol; 2016 Mar; 22(11):3105-16. PubMed ID: 27003988
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.
Fischer L; Kleeff J; Esposito I; Hinz U; Zimmermann A; Friess H; Büchler MW
Br J Surg; 2008 May; 95(5):627-35. PubMed ID: 18306152
[TBL] [Abstract][Full Text] [Related]
10. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
[TBL] [Abstract][Full Text] [Related]
11. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.
Crippa S; Partelli S; Zamboni G; Scarpa A; Tamburrino D; Bassi C; Pederzoli P; Falconi M
Surgery; 2014 Jan; 155(1):145-53. PubMed ID: 24646958
[TBL] [Abstract][Full Text] [Related]
12. Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study.
Berdelou A; Boige V; Arfi-Rouche J; Malka D; Ederhy S; Izzedine H; Leboulleux S; Chougnet CN; Burtin P; De Baere T; Laplanche A; Elias D; Schlumberger M; Scoazec JY; Ducreux M; Baudin E
Neuroendocrinology; 2017; 105(1):26-34. PubMed ID: 27225439
[TBL] [Abstract][Full Text] [Related]
13. Surgery in malignant pancreatic neuroendocrine tumors.
Nguyen SQ; Angel LP; Divino CM; Schluender S; Warner RR
J Surg Oncol; 2007 Oct; 96(5):397-403. PubMed ID: 17469119
[TBL] [Abstract][Full Text] [Related]
14. Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours.
Crona J; Norlén O; Antonodimitrakis P; Welin S; Stålberg P; Eriksson B
J Clin Endocrinol Metab; 2016 Feb; 101(2):445-52. PubMed ID: 26672633
[TBL] [Abstract][Full Text] [Related]
15. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
Wong J; Fulp WJ; Strosberg JR; Kvols LK; Centeno BA; Hodul PJ
Am J Surg; 2014 Nov; 208(5):775-780. PubMed ID: 24997491
[TBL] [Abstract][Full Text] [Related]
16. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
17. Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients.
Hayes AR; Mak IYF; Evans N; Naik R; Crawford A; Khoo B; Grossman AB; Navalkissoor S; Watkins J; Luong TV; Mandair D; Toumpanakis C; Thirlwell C; Caplin ME; Meyer T
Neuroendocrinology; 2021; 111(9):863-875. PubMed ID: 32950978
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.
Zerbi A; Capitanio V; Boninsegna L; Delle Fave G; Pasquali C; Rindi G; Campana D; Falconi M;
HPB (Oxford); 2013 Dec; 15(12):935-43. PubMed ID: 23472667
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.
Cienfuegos JA; Salguero J; Núñez-Córdoba JM; Ruiz-Canela M; Benito A; Ocaña S; Zozaya G; Martí-Cruchaga P; Pardo F; Hernández-Lizoáin JL; Rotellar F
Surg Endosc; 2017 Oct; 31(10):3847-3857. PubMed ID: 28127714
[TBL] [Abstract][Full Text] [Related]
20. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
Teh SH; Deveney C; Sheppard BC
Am J Surg; 2007 May; 193(5):610-3; discussion 613. PubMed ID: 17434366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
